ScreenerHero

IRWD Ironwood Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · ironwoodpharma.com
3.750USD+3.31%Mkt Cap: 619.65M $P/E: 4.87

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linacl…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap619.65M USD
Enterprise Value917.56M USD
Revenue (TTM)389.32M USD
Gross Profit300.62M USD
Net Income (TTM)24.02M USD
Revenue/Share2.39 USD
Last Price3.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)4.87
P/E (Forward)2.42
PEG—
EV/EBITDA3.85
EV/Revenue2.36
P/S1.54
P/B-3.71
EPS (TTM)0.77
EPS (Forward)1.50
52W Range
1.26055% of range5.780
52W High5.780 USD
52W Low1.260 USD
Profitability
Gross Margin77.22%
Oper. Margin70.16%
EBITDA Margin61.16%
Profit Margin8.11%
ROE-9.17%
ROA6.05%
Growth
Revenue Growth32.60%
Earnings Growth125.70%
Cash Flow & Leverage
Operating CF127.04M USD
CapEx (TTM)34.00K USD
FCF Margin31.29%
FCF Yield19.66%
Net Debt317.74M USD
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity-2.28
Current Ratio6.06
Quick Ratio5.84
Book Value/Sh-0.98 USD
Cash/Share0.48 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1194:1000
Split DateApr 2, 2019
Analyst Consensus
Rating—
Target (Mean)6.100 USD
Upside (mean)+62.7%
Target Range3.700 USD – 10.00 USD
3.700+62.7% to mean10.00
# Analysts4
Ownership
Shares Out.165.24M
Float136.76M
Insiders3.24%
Institutions98.88%
Short Interest
Short Ratio12.8d
Short % Float12.38%
Short % Out.11.33%
Shares Short18.73M
Short (prev mo.)18.07M
Technical
SMA 504.154 (-9.7%)
SMA 2004.000 (-6.3%)
Beta0.22
S&P 52W Chg16.45%
Avg Vol (30d)1.88M
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)39.7
MACD-0.1274
MACD Signal-0.0629
MACD Hist.-0.0645
BB Upper4.578 USD
BB Middle4.060 USD
BB Lower3.541 USD
BB Width25.54%
ATR (14)0.1965 USD
Vol Ratio (20d)1.01x